載入中
NASDAQHealthcareBiotechnology
最新資料
US$10.30
−US$0.02 · -0.19%
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
前收盤價
US$10.30
−US$0.02 · -0.19%
盤前
US$10.39
+US$0.09 · +0.87%
10月12日 上午5:51 ET
盤中時間採用ET。市場資料可能有所延遲。
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
日內區間
目前US$10.30
52週區間
目前US$10.30
盤中時間採用ET。市場資料可能有所延遲。
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
日內區間
目前US$10.30
52週區間
目前US$10.30
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.24億 USD | 7562.2萬 USD | — | — | — |
| 銷貨成本 | 835.6萬 USD | 812.1萬 USD | 622.2萬 USD | — | — |
| 毛利 | 1.15億 USD | 6750.1萬 USD | −622.2萬 USD | — | — |
| 研究與開發 | 1.42億 USD | 1.22億 USD | 1.05億 USD | 8506.1萬 USD | 5715.5萬 USD |
| 銷售、一般及管理費用 | 3638萬 USD | 3517.1萬 USD | 3203.9萬 USD | 2732.3萬 USD | 1572.7萬 USD |
| 營業費用 | 1.7億 USD | 1.49億 USD | 1.37億 USD | 1.12億 USD | 7288.2萬 USD |
| 利息收入 | 1294.2萬 USD | 1056.6萬 USD | 933.4萬 USD | 376.4萬 USD | 4.6萬 USD |
| 利息支出 | — | — | — | 376.4萬 USD | — |
| 折舊和攤銷 | 835.6萬 USD | 812.1萬 USD | 622.2萬 USD | 374.5萬 USD | 213.2萬 USD |
| 營業利益 | −5420.8萬 USD | −8111.2萬 USD | −1.43億 USD | −1.12億 USD | −7288.2萬 USD |
| 淨利 | −3862.6萬 USD | −7270萬 USD | −1.35億 USD | −1.09億 USD | −7395.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$24.83
上漲空間 141.07%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3570.54萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2202.26萬0.22%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM2012.23萬0.03%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1105.49萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO707.81萬0.05%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO593萬0.03%180億 USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS555.51萬0.02%338.69億 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB474.14萬0.05%108.2億 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
